Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy

Urology

Volumn 76, Issue 2, 2010, Pages 513.e1-513.e6

  Nisman, Benjamin ^a   Yutkin, Vladimir ^a   Nechushtan, Hovav ^a   Gofrit, Ofer N ^a   Peretz, Tamar ^a   Gronowitz, Simon ^a   Pode, Dov ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE M2; THYMIDINE KINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; TUMOR CELL; TUMOR NECROSIS; TUMOR RECURRENCE;

EID: 77955715680     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.04.034     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. R.J. Motzer, N. Agarwal, C. Beard, G.B. Bolger, B. Boston, M.A. Carducci, T.K. Choueiri, R.A. Figlin, M. Fishman, and S.L. Hancock NCCN Clinical Practice Guidelines in Oncology: kidney cancer J Natl Compr Cancer Netw 7 2009 618 630
3. P.L. Crispen, S.A. Boorjian, C.M. Lohse, B.C. Leibovich, and E.D. Kwon Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers Cancer 113 2008 450 460
4. E. Wintersberger Regulation and biological function of thymidine kinase Biochem Soc Trans 25 1997 303 308
5. Q. He, T. Fornander, H. Johansson, U. Johansson, G.Z. Hu, L.E. Rutqvist, and S. Skog Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer Anticancer Res 26 2006 4753 4759
6. P. Luo, E. He, S. Eriksson, J. Zhou, G. Hu, J. Zhang, and S. Skog Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker Eur J Cancer Prev 18 2009 220 224
7. P. Vaupel The role of hypoxia-induced factors in tumor progression Oncologist 9 Suppl 5 2004 10 17
8. P. Vaupel, and L. Harrison Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response Oncologist 9 Suppl 5 2004 4 9
9. S. Mazurek, H. Grimm, C.B. Boschek, P. Vaupel, and E. Eigenbrodt Pyruvate kinase type M2: a crossroad in the tumor metabolome Br J Nutr 87 Suppl 1 2002 S23 S29
10. E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, and R. Friis Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells Crit Rev Oncog 3 1992 91 115
11. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
12. R. Weinberger, B. Appel, A. Stein, Y. Metz, A. Neheman, and M. Barak The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma Eur J Cancer Care 16 2007 333 337
13. A. Hegele, Z. Varga, B. Kosche, T. Stief, A. Heidenreich, and R. Hofmann Pyruvate kinase type tumor M2 in urological malignancies Urol Int 70 2003 55 58
14. Z. Varga, A. Hegele, T. Stief, A. Heidenreich, and R. Hofmann Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker? Urol Res 30 2002 122 125
15. Gronowitz S. A method and kit for determination of thymidine kinase and use thereof., 2006, Vol. WO. 2006/091158 A1.
16. S.E. Lee, S.S. Byun, J.K. Oh, S.C. Lee, I.H. Chang, G. Choe, and S.K. Hong Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma J Urol 176 2006 1332 1337 discussion 1337-1338
17. L. Zini, X. Leroy, L. Lemaitre, P. Devos, S. Aubert, J. Biserte, and A. Villers Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants Eur J Surg Oncol 34 2008 687 691
18. S. Storkel, J.N. Eble, K. Adlakha, M. Amin, M.L. Blute, D.G. Bostwick, M. Darson, B. Delahunt, and K. Iczkowski Classification of renal cell carcinoma: Workgroup. No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer 80 1997 987 989
19. D.R. Cox Regression models and life-tables J R Stat Soc B Stat Methodol 34 1972 187 220
20. J. Roigas, G. Schulze, S. Raytarowski, K. Jung, D. Schnorr, and S.A. Loening Tumor M2 pyruvate kinase in plasma of patients with urological tumors Tumour Biol 22 2001 282 285
21. G.M. Oremek, N. Sapoutzis, W. Kramer, R. Bickeboller, and D. Jonas Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma Anticancer Res 20 2000 5095 5098
22. I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, and H. Zincke An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2002 2395 2400
23. M. Sorbellini, M.W. Kattan, M.E. Snyder, V. Reuter, R. Motzer, M. Goetzl, J. McKiernan, and P. Russo A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma J Urol 173 2005 48 51
24. J. Zhou, T. Schmid, S. Schnitzer, and B. Brune Tumor hypoxia and cancer progression Cancer Lett 237 2006 10 21
25. S. Kress, A. Stein, P. Maurer, B. Weber, J. Reichert, A. Buchmann, P. Huppert, and M. Schwarz Expression of hypoxia-inducible genes in tumor cells J Cancer Res Clin Oncol 124 1998 315 320
26. P. Vaupel Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis Oncologist 13 Suppl 3 2008 21 26
27. K. Kondo, M. Yao, M. Yoshida, T. Kishida, T. Shuin, T. Miura, M. Moriyama, K. Kobayashi, N. Sakai, and S. Kaneko Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters Genes Chromosomes Cancer 34 2002 58 68
28. B. Hemmerlein, A. Kugler, R. Ozisik, R.H. Ringert, H.J. Radzun, and P. Thelen Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas Virchows Arch 439 2001 645 652
29. N.B. Haas, and R. Uzzo Adjuvant therapy for renal cell carcinoma Curr Oncol Rep 10 2008 245 252